Announcement on Dilution of Immediate Returns from Issuing Convertible Bonds to Unspecified Objects, Measures to Compensate, and Commitments of Related Parties (Revised)

Guangdong Taien Kang Pharmaceutical Co., Ltd.

Announcement No.: 2026-059

Stock Code: 301263 Stock Abbreviation: Taien Kang

Announcement on Dilution of Immediate Returns from Issuing Convertible Bonds to Unspecified Objects, Measures to Compensate, and Commitments of Related Parties (Revised)

The Company and all members of the Board of Directors guarantee the content of the information disclosed is true, accurate, and complete, and that there are no false representations, misleading statements, or material omissions.

Guangdong Taien Kang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Taien Kang") plans to issue convertible corporate bonds to unspecified objects (hereinafter referred to as "convertible bonds") to raise funds not exceeding RMB 801,000,000 (inclusive) (hereinafter referred to as the "Current Offering"). In accordance with the "Opinions of the General Office of the State Council on Further Strengthening the Protection of the Legal Rights and Interests of Small and Medium Investors in the Capital Market" (Guo Ban Fa [2013] No. 110), the "Several Opinions of the State Council on Further Promoting the Healthy Development of the Capital Market" (Guo Fa [2014] No. 17), and the "Guiding Opinions on Matters Concerning the Dilution of Immediate Returns from Issuance, Refinancing, and Major Asset Restructuring" issued by the China Securities Regulatory Commission (CSRC Announcement [2015] No. 31), the Company has conducted a thorough analysis of the potential impact of the Current Offering on the equity of ordinary shareholders and immediate returns. Based on the actual situation, specific measures to compensate for the dilution of returns have been proposed, and relevant parties have made commitments to ensure the effective implementation of these measures. The details are as follows:

I. Impact of the Current Offering on the Company's Main Financial Indicators

(I) Main Assumptions and Premises for Financial Indicator Calculations

The following assumptions are solely for calculating the impact of the dilution of immediate returns from the Current Offering on the Company's main financial indicators. They do not represent the Company's judgment on future operating conditions and trends, nor do they constitute a profit forecast. The Company's actual operating conditions are subject to uncertainties influenced by national policies, industry development, and other factors. Investors should not make investment decisions based on these assumptions. The Company shall not be liable for any compensation for losses incurred by investors making investment decisions based on these assumptions. The assumptions for the impact of the dilution of immediate returns from the Current Offering on the Company's main financial indicators are as follows:

1. It is assumed that there will be no significant changes in the macroeconomic environment, industrial policies, industry development status, market conditions, or the Company's operating environment.

2. It is assumed that the issuance of convertible bonds to unspecified objects will be completed by December 31, 2026. It is further assumed that all convertible bondholders will convert their bonds by June 30, 2027 (i.e., 100% conversion rate, with all conversions occurring at once) and that no bonds will be converted by December 31, 2027 (i.e., 0% conversion rate). (This completion time is for calculation purposes only and does not constitute a commitment to the actual completion date. Investors should not make investment decisions based on this. The Company shall not be liable for any losses incurred by investors making investment decisions based on this. The final completion date will be subject to the actual completion time approved by the Shenzhen Stock Exchange for issuance and listing review and registration with the CSRC, and the time when convertible bondholders actually complete their conversions.)

3. Based on the Company's total share capital of 510,597,000 shares as of June 12, 2026, this calculation only considers the impact of the issuance of convertible bonds to unspecified objects. It does not consider changes in share capital due to subsequent repurchase and cancellation of restricted shares, granting and exercise of equity incentives, profit distribution, or capital reserve increases.